Uveal melanoma is the most common primary intraocular cancer, and after the skin, the uveal tract is the second most common location for melanoma[@b1]. However, cutaneous and uveal melanomas are different in terms of biology, natural history and response to chemotherapies[@b2].

The 5-year survival rate is 50--70% and about 50% of patients develop metastases within a median of 36 months, almost exclusively to the liver, with a median survival of 6 months after metastases[@b3].

The most frequent chromosomal abnormalities in uveal melanoma are loss of chromosome 3 and gains of 8q and 6p. Patients with chromosome 3 loss undergo the worst prognosis, whereas those with chromosome 6 (6p) gain have the best outcomes. Mutations in G-protein-α subunits GNAQ or GNA11 are observed in ≥80% of primary uveal melanomas and inactivating BAP1 mutations are found in approximately 50% of all cases, most frequently in metastatic disease. Mutations that are associated with a less aggressive behavior are those in splicing factor 3B subunit 1 (SF3B1) and eukaryotic translation initiation factor 1A, X-linked (EIF1AX)[@b4].

Local radiation therapy, using brachytherapy or alternatively, charged-particle and proton-beam radiation, is the most common approach[@b4][@b5][@b6]. Enucleation remains the only option for very large tumors.

Despite improved understanding of the disease, the overall survival (OS) rate has not increased since the 1970 s. Indeed, once uveal melanoma has metastasized to distant organs, the disease is resistant to current chemotherapies. Distant metastasis are infrequent at the time of initial presentation, occurring in \<5% of patients. For patients who develop metastasis, there is yet no standard of care. Dacarbazine, has been used for uveal melanoma, but efficacy is limited. Other chemotherapeutics, i.e. temozolomide, cisplatin, treosulfan, fotemustine and various combinations have been tested in uveal melanoma with disappointing results. A few adjuvant studies have been performed in uveal melanoma to prevent metastatic disease. However, no significant effects on metastasis free survival or OS benefit have been obtained, up to date[@b4].

In the present study, we made use of bioinformatics to analyze the data obtained from three public available microarray datasets on uveal melanoma in attempt to identify novel putative chemotherapeutic options for the metastatic disease.

Material and Methods
====================

Microarray dataset selection and meta-analysis
----------------------------------------------

The NCBI Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>)[@b7] was used to identify suitable microarray datasets comparing localized vs. metastatic uveal melanomas. Three datasets were included in the study GSE22138[@b8]- GSE73652[@b9], and GSE44295, that included whole-genome transcriptomic data from primary melanoma cells obtained upon eye enucleation ([Table 1](#t1){ref-type="table"}). The following information were extracted from each of the studies that were selected: GEO accession; sample type; platform; numbers of patients and controls; and gene expression data. Briefly, the GSE22138 dataset included 28 samples of non-metastatic tumor and 35 samples from enucleated patients having distant metastasis. Patients were included in the group of localized tumors if no metastasis were observed in 36 months of follow-up. The GSE73652 dataset included 5 samples of non-metastatic tumor and 8 samples from enucleated patients having distant metastasis. Metastasis-free cases were included only if there was \>6 years follow-up. No detailed clinical data are available for GSE44292, that included 32 samples from patients with localized disease and 24 sample from patients with metastasis. Illumina platforms were pre-processed using Bead-array prior to quantile normalization (Dunning *et al*., 2007), while Affymetrix platforms were pre-processed and quantile normalized using the robust multiarray average (RMA). The datasets were uploaded to INMEX (<http://www.inmex.ca/INMEX>)[@b10], and the data annotated by converting probe ID to Entrez IDs. For each probe-set, intensity values were auto-scaled and a data integrity check was performed prior to the meta-analysis stage. Batch effects were corrected using the "ComBat" function. A random effects model of effect size (ES) measure was used to integrate gene expression patterns from the three datasets. The random effects model presumes that different studies present substantial diversity, and evaluates between-study variance as well as within-study sampling error. Genes with FDR \< 0.01 were identified as Differentially Expressed (DE) and selected for further analysis.

Gene Ontology (GO) and Drug Prediction Analysis
-----------------------------------------------

Functional relationships among DE gene were obtained from GeneMania (<http://genemania.org/> <http://genemania.org/>)[@b11]. GeneMANIA searches publicly available genomics and proteomics data, including data from gene and protein expression profiling studies and primary and curated molecular interaction networks and pathways, to find related genes. The network weighting method is 'Gene-Ontology (GO) based weighting, Biological Process based'. This weighting method assumes the input gene list is related in terms of biological processes (as defined by GO).

The PANTHER (protein annotation through evolutionary relationship) classification system[@b12] (<http://www.pantherdb.org/>) was used to classify input genes according to their function (PANTHER protein class). PANTHER is a comprehensive system that combines gene function, ontology, pathways and statistical tools that enable to analyze large-scale, genome-wide data from sequencing, proteomics or gene expression experiments.

The L1000CDS^2^ was used to identify potential chemotherapeutics for metastatic uveal melanoma. L1000CDS^2^ enables to find L1000 small molecule signatures that match input gene signatures. The L1000 mRNA gene-expression dataset is generated as part of the Library of Integrated Network-based Cellular Signatures (LINCS) project, a NIH Common Fund program. LINCS aims to profile the molecular effects of small molecules on human cells[@b13]. When gene lists are submitted to L1000CDS^2^, the search engine compares the input gene lists to the DE genes computed from the LINCS L1000 data and returns the top 50 matched signatures. The result score is the overlap between the input DE genes and the signature DE genes divided by the effective input. The effective input is the length of the intersection between the input genes and the L1000 genes. L1000CDS^2^ currently covers chemically perturbed gene expression profiles from 62 cell-lines and 3,924 small molecules. Also, L1000CDS^2^ allows to predict effective drug combinations by comparing every possible pair among the top 50 signatures and computing the potential synergy for each pair.

Results
=======

Meta-analysis of gene expression in metastatic uveal melanoma
-------------------------------------------------------------

Three GEO data sets were identified for the following analysis ([Table 1](#t1){ref-type="table"}). These datasets consisted of primary uveal melanoma data, and included a total of 67 metastatic tumors and 65 localized primary tumors. Details of the individual studies are presented in [Table 1](#t1){ref-type="table"}. [Figure 1A](#f1){ref-type="fig"} shows a Principal Component Analysis of the three separate microarray datasets included in the meta-analysis.

A total of 64 genes were identified, which were consistently modulated in metastatic tumors. Among these 64 DE genes, 29 were upregulated and 35 were downregulated. A list of the significant upregulated and downregulated genes is shown in [Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}, respectively. An heatmap showing the 64 DE genes is presented in [Fig. 1B](#f1){ref-type="fig"}. The functional relationships among the up- and down-regulated genes, respectively, are presented in [Fig. 2A,B](#f2){ref-type="fig"}. Among the upregulated genes, the top three represented protein classes were: Transferase, which included phosphatases (CDC25B and IMPA1) and proteases (IDE and TYSND1); Enzyme Modulator, including G protein modulators (SGSM2, SRGAP2 and SIPA1L2) and the protease inhibitor, HPN; Nucleic Acid Binding, i.e. the DNA helicase, CHD7, and the DNA ligase, LIG1 ([Fig. 2C](#f2){ref-type="fig"}).

Among the downregulated genes, the top three protein classes represented were: Nucleic Acid Binding, that included DNA binding proteins (H2AFY2, NDN and MBNL1) and RNA binding proteins (ANG, EIF4A2 and EIF4A3); Hydrolase, including the proteases, ABHD6 and LTA4H, and the lipase, PLCD1; Enzyme Modulator, including the G protein modulator, PLCD1, the kinase modulator, HOOK1, and the protease inhibitor, VWA5A ([Fig. 2D](#f2){ref-type="fig"}).

Prediction of novel chemotherapeutics for metastatic uveal melanoma
-------------------------------------------------------------------

The L1000CDS^2^ web-based utility was used to predict small molecules and drugs targeting the metastatic uveal melanoma gene signature. [Figure 3](#f3){ref-type="fig"} shows a clustergram with the top ranked L1000 perturbations (e.g. those with most anti-similar signatures). The complete list of predicted chemotherapeutics is presented as [Table 4](#t4){ref-type="table"}. Several of these drugs are FDA-approved and already used in the clinic or tested in clinical trials, as indicated in [Table 4](#t4){ref-type="table"}. Among the predicted chemotherapeutics, the most represented classes were: histone deacetylase inhibitors (that included HDAC6 inhibitor ISOX, BRD-K13810148, Trichostatin A and Vorinostat), and anti-infectious/parasitic drugs (i.e., Clofazimine, Erythromycin ethylsuccinate, Demeclocycline and Quinacrine hydrochloride). The top identified drugs were the following: BRD-K07220430 (Cinnarizine), an anti-histaminic drug used for motion sickness, was predicted for its ability to downregulate CHAC1 and to upregulate MBNL1, LPAR6, PLSCR4, NDN, ABHD6, ZSCAN18 and ZBTB20; Digitoxigenin, for its ability to downregulate CDC25B, IDE, INTS8 and MTDH, while upregulating F11R, ID2, and RAB11FIP1; clofazimine, a fat-soluble iminophenazine used in leprosy, which is able to downregulate CDC25B, CHAC1, and SHC1, and to upregulate ABHD6, PLOD2, PLSCR4, ZBTB20, ZSCAN18. Accordingly, the top three most promising drug combination found were: BRD-K07220430 and Digitoxigenin; Digitoxigenin and OSSK_645683; BRD-K07220430 and HDAC6 inhibitor ISOX (for the complete list, see [Table 5](#t5){ref-type="table"}).

Discussion
==========

Melanoma of the uveal tract accounts for 5% of all melanomas and, with an incidence of about 6 cases per million person--years, represents the most common primary intraocular malignancy[@b14][@b15]. Despite improvements in diagnosis and more effective local therapies for primary cancer, the rate of metastatic death has not changed in the past forty years[@b15].

Several genes and pathways have been identified to be involved in the progression and metastasis of uveal melanoma, such as c-Met[@b16], Hepatocyte Growth Factor (HGF)[@b16][@b17], Insulin-like Growth Factor-1 Receptor (IGF-1R)[@b18], the CXCL12-CXCR4 pathway[@b17][@b19], VEGF[@b20], Mda-9/syntenin[@b21] and the PTP4A3 phosphatase[@b8]. However, despite increasing knowledge in the biology of uveal melanoma, no therapeutic strategies has been found to be effective. Metastatic uveal melanoma is resistant to current systemic chemotherapy and, to date, no clear role has been established for chemotherapy in several clinical trials, that reported objective response rates \<20%[@b4]. Single-agent chemotherapies (e.g., dacarbazina, fotemustine, paclitaxel, temozolomide, camptothecin, treosulfan) or combination chemotherapies (e.g. gemcitabine/treosulfan, cisplatin/gemcitabine/treosulfan, carboplatin/paclitaxel/sorafenib) have shown poor response rates and immunotherapy with ipilimumab, antiangiogenetic treatment strategies using bevacizumab combined with interferon-α2b, temozolomide, or aflibercept have not proven to be superior to chemotherapy[@b22].

In order to prevent metastatic disease, several adjuvant studies are also being conducted using ipilimumab, sunitinib, valproic acid, and crizotinib for high-risk patients[@b4]. Adjuvant treatment with bacillus Calmette-Guerin and interferon-α, as well as, intra-arterial hepatic infusion of fotemustine, have been previously studied in an effort to reduce the occurrence of liver metastasis, but none of these studies has demonstrated significant improvement in metastasis free survival or OS[@b4].

The limited efficacy of current chemotherapies proves the medical need for more effective treatment strategies in metastatic uveal melanoma. In the present study, a meta-analysis of three whole-genome microarray datasets on primary tumor samples from the enucleated eyes of patients with localized or metastatic disease, has been performed in order to investigate the genes associated to the metastatic properties of uveal melanoma and to identify potential chemotherapeutic strategies to be used in metastatic disease.

It was recently developed a 15-gene qPCR-based assay that discriminate between primary uveal melanomas that have a low metastatic risk and a high metastatic risk [@b23]. This platform is currently used in a College of American Pathologists (CAP)-accredited Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory on fine needle aspiration samples and on formalin-fixed specimens[@b23]. A few of the genes screened in this assay correspond to those identified by the current analysis, namely ID2 and LTA4H, among the downregulated genes. Some of the other DE genes, share similar function to those included in the assay, i.e. EIF4A2 and EIF4E2 (to EIF1B).

As regards the putative drugs here identified, some of them are already in clinical use, such as BRD-K07220430 (Cinnarizine)[@b24], clofazimine[@b25], mesoridazine besylate[@b26], erythromycin ethylsuccinate[@b27]; other are in preclinical development (e.g. HDAC6 inhibitor ISOX)[@b28] or do not have any known pharmacological target, e.g. OSSK_645683. Interestingly, some of the identified drugs are histone deacetylase inhibitors (such as, HDAC6 inhibitor ISOX, BRD-K13810148, Trichostatin A and Vorinostat), that have already been shown efficacy on uveal melanoma preclinical models[@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36]. Klisovic and collaborators have shown that the histone deacetylase inhibitor, Depsipeptide (FR901228), inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines[@b35], as well as it is able to inhibit *in vitro* uveal melanoma cell lines migration via downregulation of Matrix MetalloProteinases 2, 9 and Membrane Type-1/MMP (MMP-2, MMP-9 and MT-1/MMP) and the upregulation of Tissue Inhibitors of Matrix MetalloProteinases 1 and 2 (TIMP-1 and TIMP-2)[@b34]. Chen and collaborators have shown that microRNA-137 and microRNA-124a act as a tumor suppressors in uveal melanoma and could be successfully silenced by using the histone deacetylase inhibitor, trichostatin A[@b32][@b36]. Landreville and collegues have shown that in three uveal melanoma cell lines (92.1, OCM1A, and Mel202), Trichostatin A was able to reduce the fraction of viable cells and increase the proportion of cells undergoing apoptosis[@b33]. Also, it was shown that Quisinostat (a Class I and II histone deacetylase inhibitor) inhibited the migration and proliferation of 92.1 and OMM2.3 cell lines in zebrafish xenograft embryos[@b30]. In addition, the Class III-specific HDAC inhibitor, Tenovin-6, was shown to be able to eradicate cancer stem cells in 92.1 and Mel 270 cells[@b29]. Venza in 2014[@b31], reported that the Class-I histone deacetylase inhibitor, MS-275, due to its ability to reduce c-FLIP expression, is able to increase TRAIL-induced cell death in uveal melanoma cell lines. MS-275, is currently tested in a Phase 1 study for the treatment of patients with Refractory Solid Tumors, including intraocular melanoma, or Lymphomas (NCT00020579). Vorinostat, a small molecule inhibitor of class I and II histone deacetylases, is currently tested in two Phase 2 Study on Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma and Grade IV Metastatic Uveal Melanoma (NCT00121225, NCT 01587352).

The utility of the present data may reside primarily in the potential identification of effective adjuvant treatments. In light of the fact that there is no therapy for metastatic disease, the most promising strategy to improve survival is to treat patients in an adjuvant setting. Although there might be non- metastasizing melanomas, which never metastasize, even if not treated, however the intra-tumoral genetic heterogeneity suggests an ongoing evolutionary tumoral process[@b37]. Adjuvant interventions could settle up the uncertainty about the effect of ocular treatment on survival, since some patients might unnecessarily sacrifice their visus in the hope of a longer life-expectancy; while other patients with small melanomas might succumb due to metastasis because treatment has been delayed. Presently, there is no adjuvant approach that improves outcome, but the impact of ocular treatment, in terms of therapeutic benefit, has ethical implications.

The present study has several advantages but also limitations. It represents, to date, the largest meta-analysis comparing metastatic vs. non metastatic uveal melanomas, encompassing whole-genomic data from a total of 132 patients. A strict and rigorous statistics has been applied to data in order to sort out the most relevant genes characterizing the spreading of tumor to the liver. Among the upregulated genes, the highest effect size was detected for JPH1, encoding for Junctophilin-1, a component of junctional complexes between the plasma membrane and endoplasmic/sarcoplasmic reticulum, providing functional cross-talk between the cell surface and intracellular calcium release channels (<http://www.genecards.org/cgi-bin/carddisp.pl?gene=JPH1>). Among the significant downregulated genes, the gene with the highest effect size was PLSCR4, encoding for the Phospholipid Scramblase 4, which has been found to be strongly expressed in the neuropil of malignant gliomas and in cytoplasm of liver cancers, colorectal cancers and malignant melanomas (<http://www.proteinatlas.org/ENSG00000114698-PLSCR4/cancer>). Comparing to the original analysis, the PTP4A3 phosphatases and the cancer-testis antigen, PRAME, were dropped out because of too little statistical significance. In addition, although the role of the PKC, MAPK and PI3K/AKT/mTOR signaling cascades has been extensively examined in uveal melanoma[@b38][@b39][@b40], however, whole genome transcriptomic analysis may fail to detect their modulation, because of the primary contribution related to post-transcriptional modifications. Also, our analysis was very statistical stringent (FDR \< 0.01), and this may account for the differences from previously published work[@b1]. Furthermore, the discrepancies with previous analysis may be due to the enlargement of the number of samples which could influence DE genes detection as respect to smaller sample groups.

Investigating the genes found to be significantly modulated in the present analysis may help to identify the molecular mechanisms involved in the liver metastasis of uveal melanoma, and may allow the identification of novel pharmacological targets for the prevention and treatment of liver involvement. Moreover, our study was aimed at predicting putative pharmacological schemes to apply as adjuvant or curative therapy, making use of the Library of Integrated Network-based Cellular Signatures (LINCS) project database. The repurposing of drugs currently approved for use in the clinical setting may expedite the design of phase II-III clinical trials, being cost-effective and reducing the risks associated with early stages of drug development[@b41]. The highest ranking scores were found for Cinnarizine, Digitoxigenin and Clofazimine. Cinnarizine has already been shown to be effective *in vitro* against lymphoma and multiple myeloma[@b42] and to inhibit melanogenesis in mouse B16 melanoma cells[@b43], and Clofazimine was found effective in preclinical models of pancreatic ductal adenocarcinoma and triple-negative breast cancer[@b44][@b45].

However, this study has also limitations. Despite the practicality of this bioinformatic approach, there are drawbacks to point out. First, the efficacy of a drug is more complex than the simple match of expression profiles. Drugs have to reach tissue-specific concentrations to exert an effect, and the route and timing of administration is essential for the drug to be effective and to limit side effects. A preliminary *in vitro* testing on both primary and established cancer cell lines will be required before running pilot phase II clinical trials. On the other hand, for successful result of the clinical trials, the appropriate selection and recruitment of patients will be also key to evaluate the potential activity of the compounds in the clinical setting.
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###### Characteristics of the microarray datasets included in the meta-analysis.

  Study    GEO accession                                                   Patients                                                                                          Samples                                               Platform        
  ------- --------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- --------------------- -------------------------------
  1          GSE22138      28 Mean age: 59.1 Chr3 monosomy: 10/28; Partial alteration: 2/28; Not available:2/28 36 months follow-up   35 Mean age: 60.5 Chr3 monosomy: 22/35; Partial alteration: 3/35; Not available: 6/35   Primary tumor (eye)      Affymetrix U133 plus 2
  2          GSE44295                                                         32                                                                                               24                                             Primary tumor (eye)   Illumina Human ref. [@b8] v.3
  3          GSE73652                                               5 \> 6 years follow-up                                                                                      8                                             Primary tumor (eye)     Illumina Human HT 12 v. 4

###### List of significantly upregulated genes in metastatic uveal melanoma.

  Name        Combined Effect Size      FDR
  ---------- ---------------------- ------------
  JPH1              −1.1736          1.5378e-05
  TACC2             −0.97146         0.00059404
  SIPA1L2           −0.96664         0.00059404
  TYSND1            −0.9641          0.00059404
  TMEM161A          −0.95064          0.003168
  MCU               −0.94061         0.00094886
  PRKDC             −0.93729         0.00094886
  MTFR1             −0.90776         0.0015792
  SHC1              −0.86702          0.003168
  MYEOV             −0.86335          0.003168
  VCPIP1            −0.85848          0.003168
  CHAC1             −0.8543           0.003168
  HPN               −0.85398          0.003168
  SUMF2             −0.85012         0.0049617
  LIG1              −0.83865         0.0040445
  RNF19A            −0.83777         0.0040445
  TAF5              −0.8377          0.0040445
  HRSP12            −0.83574          0.009672
  CDC25B            −0.83518         0.0040445
  IMPA1             −0.82144         0.0048032
  SGSM2             −0.81096         0.0052385
  SRGAP2            −0.80528         0.0057402
  MORC2             −0.79995         0.0057952
  C8orf76           −0.79478         0.0059805
  TMEM70            −0.79037         0.0063563
  IDE               −0.78739         0.0065272
  CHD7              −0.78327         0.0071536
  MTDH              −0.7758          0.0082124
  INTS8             −0.75952          0.009672

###### List of significantly downregulated genes in metastatic uveal melanoma.

  Name         Combined Effect Size      FDR
  ----------- ---------------------- ------------
  PLSCR4              1.1795          0.0072336
  RAB11FIP1           1.0587          0.00013411
  MEGF10              1.0539          0.00013411
  ID2                 1.0091          0.00046632
  VWA5A              0.93182           0.005083
  TRAK1              0.91734          0.0014595
  MPPED2             0.90563          0.0015792
  ANG                0.89382          0.0050995
  DLC1               0.87069           0.003168
  NDN                0.86139           0.003168
  PLCD1              0.85619           0.003168
  EFCAB1              0.8339           0.004092
  ACAA1               0.8233          0.0048032
  LPIN1              0.82127          0.0048032
  LTA4H              0.81998          0.0048032
  BMI1               0.80767          0.0086087
  NFIA               0.80698          0.0057402
  PRICKLE2           0.80144          0.0057952
  H2AFY2              0.8013          0.0057952
  SETMAR             0.79757          0.0059412
  PLOD2              0.79556          0.0059805
  EIF4A2             0.79517          0.0059805
  FAM24B             0.79409          0.0059805
  ZSCAN18            0.78983          0.0063563
  MKRN2              0.78026          0.0071738
  F11R               0.77016          0.0084361
  HOOK1              0.76951           0.00849
  EIF4E3             0.76619          0.0089451
  LPAR6              0.76421          0.0092481
  MID1                0.7632          0.0091958
  ZBTB20             0.76021           0.009672
  ABHD6              0.76011           0.009672
  MBNL1              0.75836           0.009672
  SHE                0.75664          0.0098953
  ZNF415             0.75661           0.009672

###### Predicted small molecules and drugs targeting the metastatic uveal melanoma gene signature.

  Rank    Score             Perturbation                 Class[\*](#t4-fn1){ref-type="fn"}       FDA status[\*](#t4-fn1){ref-type="fn"}           Indications[\*](#t4-fn1){ref-type="fn"}
  ------ -------- --------------------------------- ------------------------------------------- ---------------------------------------- ----------------------------------------------------------
  1       0.1569     BRD-K07220430 (Cinnarizine)                  Anti-histaminic                               Approved                                      Motion sickness.
  2       0.1373            Digitoxigenin                             Unknown                                 Not approved                                          None
  3       0.1373             clofazimine                         Antimycobacterial                              Approved                                          Leprosy
  4       0.1373             OSSK_645683                              Unknown                                 Not approved                                          None
  5       0.1373          MLS-0091942.0001                            Unknown                                 Not approved                                          None
  6       0.1373        Mesoridazine besylate                       Neuroleptic                                 Approved                                       Schizophrenia
  7       0.1176        HDAC6 inhibitor ISOX               Histone deacetylase inhibitor                      Not approved                                          None
  8       0.1176            BRD-K13810148                 Histone deacety-lase inhibitor                    Investigational                                           
  9       0.1176          HY-11005 (BX-912)                       PDK1 inhibitor                              Not approved                                          None
  10      0.1176              SB 334867                          Orexin antagonist                            Not approved                                          None
  11      0.1176               SC 560                        Cyclooxygenase inhibitors                        Not approved                                          None
  12      0.1176     ERYTHROMYCIN ETHYLSUCCINATE               Macrolide antibiotic                             Approved                                    Bacterial infection
  13      0.1176   Huperzine A \[(−)-Huperzine A\]   Reversible acetylcholinesterase inhibitor              Investigational                                 Alzheimer's disease
  14      0.1176       FLUOCINOLONE ACETONIDE                     Glucocorticoid                                Approved                                       Skin disorders
  15      0.1176               PP-110                           Topical anesthetic                          Investigational                                     Hemorrhoids
  16      0.1176              NSC 23766                           RAC1 inhibitor                                                                                      
  17      0.1176             MLS-0390979                         Inhibitor of IAPs                                                                                    
  18      0.1176           NCGC00229596-01                            Unknown                                 Not approved                                          None
  19      0.1176            BRD-K73567619                             Unknown                                 Not approved                                          None
  20      0.1176            BRD-K24281017                             Unknown                                 Not approved                                          None
  21      0.1176            BRD-K06217810                             Unknown                                 Not approved                                          None
  22      0.1176               5922592                                Unknown                                 Not approved                                          None
  23      0.1176            BRD-K11778372                             Unknown                                 Not approved                                          None
  24      0.1176                1495                                  Unknown                                 Not approved                                          None
  25      0.1176                G-220                                 Unknown                                 Not approved                                          None
  26      0.1176            BRD-K61192129                             Unknown                                 Not approved                                          None
  27      0.1176            BRD-K75958195                             Unknown                                 Not approved                                          None
  28      0.1176            BRD-K50311478                             Unknown                                 Not approved                                          None
  29      0.1176            BRD-K96402602                             Unknown                                 Not approved                                          None
  30      0.1176            BRD-K94920105                             Unknown                                 Not approved                                          None
  31      0.1176            BRD-K48692744                             Unknown                                 Not approved                                          None
  32      0.1176            BRD-K12765235                             Unknown                                 Not approved                                          None
  33      0.1176            BRD-K15715913                             Unknown                                 Not approved                                          None
  34      0.1176           demeclocycline              Semisynthetic tetracycline antibiotic                    Approved                             Lyme disease, acne, and bronchitis
  35      0.1176            BRD-K49519144                             Unknown                                 Not approved                                          None
  36      0.0980           trichostatin A                 Histone deacety-lase inhibitor                      Not approved                                          None
  37      0.0980    Dorsomorphin dihydrochloride                  AMPK inhibitor                              Not approved                                          None
  38      0.0980        HDAC6 inhibitor ISOX              Histone deacety-lase inhibitor                      Not approved                                          None
  39      0.0980        16-HYDROXYTRIPTOLIDE                          Unknown                                 Not approved                                          None
  40      0.0980            BRD-K92317137                             Unknown                                 Not approved                                          None
  41      0.0980      QUINACRINE HYDROCHLORIDE                    Anti-helmintic                                Approved                  Giardiasis, cutaneous leishmaniasis, malignant effusions
  42      0.0980        HDAC6 inhibitor ISOX              Histone deacety-lase inhibitor                      Not approved                                          None
  43      0.0980            BRD-K84203638                                                                     Not approved                                          None
  44      0.0980           trichostatin A                 Histone deacety-lase inhibitor                      Not approved                                          None
  45      0.0980            BRD-K92158425                                                                     Not approved                                          None
  46      0.0980            topotecan hcl                  DNA topoisomerases inhibitor                         Approved                                           Cancer
  47      0.0980            BRD-A60245366                             Unknown                                 Not approved                                          None
  48      0.0980               EI-293                                 Unknown                                 Not approved                                          None
  49      0.0980                S1003                                 Unknown                                 Not approved                                          None
  50      0.0980             vorinostat                   Histone deacetylase inhibitors                        Approved                                 Cutaneous T-cell lymphoma

^\*^Information obtained from DrugBank (<https://www.drugbank.ca/>).

###### Top 50 predicted small molecule combinations targeting the metastatic uveal melanoma gene signature.

  Rank    Score           Combination         
  ------ -------- --------------------------- ----------------------------------
  1       0.2941       1\. BRD-K07220430              2\. Digitoxigenin
  2       0.2745       2\. Digitoxigenin               4\. OSSK_645683
  3       0.2745       1\. BRD-K07220430           7\. HDAC6 inhibitor ISOX
  4       0.2745       1\. BRD-K07220430              8\. BRD-K13810148
  5       0.2745       1\. BRD-K07220430       12\. ERYTHROMYCIN ETHYLSUCCINATE
  6       0.2745       1\. BRD-K07220430             18\. NCGC00229596-01
  7       0.2745       1\. BRD-K07220430              30\. BRD-K94920105
  8       0.2549       2\. Digitoxigenin               3\. clofazimine
  9       0.2549       2\. Digitoxigenin             5\. MLS-0091942.0001
  10      0.2549       2\. Digitoxigenin          6\. Mesoridazine besylate
  11      0.2549        3\. clofazimine            7\. HDAC6 inhibitor ISOX
  12      0.2549        4\. OSSK_645683            7\. HDAC6 inhibitor ISOX
  13      0.2549   6\. Mesoridazine besylate       7\. HDAC6 inhibitor ISOX
  14      0.2549        3\. clofazimine               8\. BRD-K13810148
  15      0.2549        4\. OSSK_645683               8\. BRD-K13810148
  16      0.2549   6\. Mesoridazine besylate          8\. BRD-K13810148
  17      0.2549       1\. BRD-K07220430                 9\. HY-11005
  18      0.2549     5\. MLS-0091942.0001               10\. SB 334867
  19      0.2549        4\. OSSK_645683        12\. ERYTHROMYCIN ETHYLSUCCINATE
  20      0.2549   6\. Mesoridazine besylate   12\. ERYTHROMYCIN ETHYLSUCCINATE
  21      0.2549       1\. BRD-K07220430                16\. NSC 23766
  22      0.2549        4\. OSSK_645683                 16\. NSC 23766
  23      0.2549     5\. MLS-0091942.0001               16\. NSC 23766
  24      0.2549       1\. BRD-K07220430               17\. MLS-0390979
  25      0.2549     5\. MLS-0091942.0001            18\. NCGC00229596-01
  26      0.2549       1\. BRD-K07220430              20\. BRD-K24281017
  27      0.2549     5\. MLS-0091942.0001             20\. BRD-K24281017
  28      0.2549       2\. Digitoxigenin              23\. BRD-K11778372
  29      0.2549       2\. Digitoxigenin                  24\. 1495
  30      0.2549       2\. Digitoxigenin                  25\. G-220
  31      0.2549       2\. Digitoxigenin              26\. BRD-K61192129
  32      0.2549        4\. OSSK_645683               26\. BRD-K61192129
  33      0.2549       2\. Digitoxigenin              27\. BRD-K75958195
  34      0.2549       1\. BRD-K07220430              29\. BRD-K96402602
  35      0.2549       1\. BRD-K07220430              32\. BRD-K12765235
  36      0.2549       1\. BRD-K07220430              33\. BRD-K15715913
  37      0.2549       2\. Digitoxigenin              33\. BRD-K15715913
  38      0.2549        3\. clofazimine               33\. BRD-K15715913
  39      0.2549     5\. MLS-0091942.0001             33\. BRD-K15715913
  40      0.2549       1\. BRD-K07220430          39\. 16-HYDROXYTRIPTOLIDE
  41      0.2549       1\. BRD-K07220430          42\. HDAC6 inhibitor ISOX
  42      0.2549       1\. BRD-K07220430              43\. BRD-K84203638
  43      0.2549       1\. BRD-K07220430             44\. trichostatin A
  44      0.2549       1\. BRD-K07220430              46\. topotecan hcl
  45      0.2549       1\. BRD-K07220430               50\. vorinostat
  46      0.2353        4\. OSSK_645683              5\. MLS-0091942.0001
  47      0.2353       1\. BRD-K07220430          6\. Mesoridazine besylate
  48      0.2353        4\. OSSK_645683           6\. Mesoridazine besylate
  49      0.2353        4\. OSSK_645683                  9\. HY-11005
  50      0.2353     5\. MLS-0091942.0001                9\. HY-11005
